eflornithine has been researched along with Cancer of Skin in 48 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines." | 3.67 | Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. ( Benjamin, R; Gutterman, J; Kantarjian, H; Plager, C; Quesada, J; Talpaz, M, 1986) |
| "Prevention of nonmelanoma skin cancers remains a health priority due to high costs associated with this disease." | 2.82 | Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. ( Alberts, DS; Bartels, HG; Bartels, P; Bermudez, Y; Curiel-Lewandrowski, C; Einspahr, JG; Hu, C; Jeter, JM; Myrdal, PB; Stratton, SP; Warneke, JA; Yozwiak, M, 2016) |
| " Our intention was to retrospectively assess the further incidence of skin cancer, other malignancies, and adverse events of patients accrued to our phase III skin cancer prevention study of DFMO." | 2.77 | A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. ( Bailey, HH; Borich, A; Havighurst, T; Kim, K; Kreul, SM; Mendonça, EA; Snow, S; Verma, A; Wood, GS, 2012) |
| "Subjects with a history of skin cancer taking daily DFMO had an insignificant reduction (P = 0." | 2.75 | A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. ( Bailey, HH; Berg, ER; Carbone, PP; Douglas, J; Dreckschmidt, NE; Hamielec, M; Havighurst, TC; Kim, K; Larson, PO; Lenaghan, T; Pomplun, M; Puchalsky, D; Sharata, HH; Sielaff, K; Snow, S; Verma, AK; Viner, JL, 2010) |
| "More than one million new skin cancers are diagnosed yearly in the United States creating the need for effective primary and chemopreventive strategies to reduce the incidence, morbidity, and mortality associated with skin cancer." | 2.70 | Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. ( Alberts, DS; Bowden, GT; Einspahr, JG; Nelson, MA; Saboda, K; Warneke, J, 2002) |
| " The dosage of PXM 10 mg q." | 2.69 | Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. ( Blair, IA; Carbone, PP; Douglas, JA; Larson, PO; Pomplun, M; Tutsch, KD; Verma, AK, 1998) |
| "The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate." | 2.41 | The state-of-the-art in chemoprevention of skin cancer. ( Alberts, DS; Dorr, RT; Stratton, SP, 2000) |
| "Melanoma is a disease that need not be deadly." | 2.38 | The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993) |
| "Non-melanoma skin cancer (NMSC) is the most common form of skin cancer." | 1.40 | Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2014) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Non-melanoma skin cancer (NMSC) is the most common type of skin cancer in Caucasian populations." | 1.39 | Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. ( Afaq, F; Arumugam, A; Athar, M; Chaudhary, SC; Elmets, CA; Kopelovich, L; Talwelkar, SS; Weng, Z, 2013) |
| "Nonmelanoma skin cancer is a common cancer type with increasing incidence." | 1.39 | Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "With the incidence of nonmelanoma skin cancer on the rise, current prevention methods, such as the use of sunscreens, have yet to prove adequate to reverse this trend." | 1.37 | New agents for prevention of ultraviolet-induced nonmelanoma skin cancer. ( Athar, M; Camp, WL; Elmets, CA; Turnham, JW, 2011) |
| " This paper discusses the development of a group of lipophilic polyamine analogues that potently inhibit the cellular polyamine uptake system and greatly increase the effectiveness of polyamine depletion when used in combination with DFMO, a well-studied polyamine biosynthesis inhibitor." | 1.35 | Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. ( Burns, MR; Chen, Y; Graminski, GF; O'Brien, TG; Weeks, RS, 2009) |
| "However, DFMO treatment led to marked hair loss in PKC epsilon transgenic mice." | 1.32 | Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. ( Ness, KJ; Oberley, TD; Verma, AK; Wheeler, DL, 2003) |
| "The probes also located squamous cell carcinoma cells in human skin." | 1.28 | Fluorescent location of ornithine decarboxylase employing derivatives of the specific inhibitor alpha-difluoromethyl ornithine. ( Steven, FS; Tucker, DF; Warne, P; Williams, LA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (16.67) | 18.7374 |
| 1990's | 13 (27.08) | 18.2507 |
| 2000's | 14 (29.17) | 29.6817 |
| 2010's | 12 (25.00) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, MR | 1 |
| Graminski, GF | 1 |
| Weeks, RS | 1 |
| Chen, Y | 1 |
| O'Brien, TG | 2 |
| Chow, CL | 1 |
| Havighurst, T | 2 |
| Lozar, T | 1 |
| Jones, TD | 1 |
| Kim, K | 3 |
| Bailey, HH | 3 |
| Xu, D | 1 |
| Zhao, H | 1 |
| Sun, J | 1 |
| Pommergaard, HC | 3 |
| Burcharth, J | 3 |
| Rosenberg, J | 3 |
| Raskov, H | 3 |
| Arumugam, A | 1 |
| Weng, Z | 1 |
| Talwelkar, SS | 1 |
| Chaudhary, SC | 1 |
| Kopelovich, L | 1 |
| Elmets, CA | 2 |
| Afaq, F | 1 |
| Athar, M | 2 |
| Jeter, JM | 2 |
| Curiel-Lewandrowski, C | 1 |
| Stratton, SP | 2 |
| Myrdal, PB | 1 |
| Warneke, JA | 1 |
| Einspahr, JG | 2 |
| Bartels, HG | 1 |
| Yozwiak, M | 1 |
| Bermudez, Y | 1 |
| Hu, C | 1 |
| Bartels, P | 1 |
| Alberts, DS | 5 |
| Verma, AK | 10 |
| Sielaff, K | 1 |
| Larson, PO | 3 |
| Snow, S | 3 |
| Lenaghan, T | 1 |
| Viner, JL | 1 |
| Douglas, J | 1 |
| Dreckschmidt, NE | 2 |
| Hamielec, M | 1 |
| Pomplun, M | 2 |
| Sharata, HH | 1 |
| Puchalsky, D | 1 |
| Berg, ER | 1 |
| Havighurst, TC | 1 |
| Carbone, PP | 3 |
| Ramot, Y | 1 |
| Pietilä, M | 1 |
| Giuliani, G | 1 |
| Rinaldi, F | 1 |
| Alhonen, L | 1 |
| Paus, R | 1 |
| Camp, WL | 1 |
| Turnham, JW | 1 |
| Prado, R | 1 |
| Francis, SO | 1 |
| Mason, MN | 1 |
| Wing, G | 1 |
| Gamble, RG | 1 |
| Dellavalle, R | 1 |
| Kreul, SM | 1 |
| Mendonça, EA | 1 |
| Wood, GS | 1 |
| Borich, A | 1 |
| Verma, A | 1 |
| Fischer, SM | 2 |
| Conti, CJ | 1 |
| Viner, J | 1 |
| Aldaz, CM | 1 |
| Lubet, RA | 2 |
| Wheeler, DL | 2 |
| Ness, KJ | 1 |
| Oberley, TD | 1 |
| Hobbs, CA | 1 |
| Paul, BA | 1 |
| Gilmour, SK | 3 |
| Feith, DJ | 1 |
| Bol, DK | 1 |
| Carboni, JM | 1 |
| Lynch, MJ | 1 |
| Sass-Kuhn, S | 1 |
| Shoop, PL | 1 |
| Shantz, LM | 2 |
| Hess, LM | 1 |
| Saboda, K | 2 |
| Malone, DC | 1 |
| Salasche, S | 1 |
| Warneke, J | 2 |
| Levin, VA | 1 |
| Boutwell, RK | 3 |
| Takigawa, M | 3 |
| Ashendel, CL | 1 |
| Simsiman, RC | 2 |
| Weeks, CE | 1 |
| Herrmann, AL | 1 |
| Nelson, FR | 1 |
| Slaga, TJ | 1 |
| Greene, MH | 1 |
| Ootsuyama, A | 1 |
| Tanooka, H | 1 |
| Peralta Soler, A | 1 |
| Gilliard, G | 1 |
| Megosh, L | 1 |
| George, K | 1 |
| Mitsunaga, S | 1 |
| Clapper, M | 1 |
| Litwin, S | 1 |
| Watts, P | 1 |
| Bauer, B | 1 |
| Klein-Szanto, AJ | 1 |
| Smith, MK | 1 |
| Trempus, CS | 1 |
| Douglas, JA | 2 |
| Blair, IA | 1 |
| Tutsch, KD | 2 |
| Bomser, JA | 1 |
| Singletary, KW | 1 |
| Wallig, MA | 1 |
| Smith, MA | 1 |
| Arbeit, JM | 1 |
| Riley, RR | 1 |
| Huey, B | 1 |
| Porter, C | 1 |
| Kelloff, G | 1 |
| Lubet, R | 1 |
| Ward, JM | 1 |
| Pinkel, D | 1 |
| Dorr, RT | 1 |
| Lan, L | 1 |
| Trempus, C | 1 |
| Lee, M | 1 |
| Pirsch, JD | 1 |
| Thomas, JP | 1 |
| Pauk, D | 1 |
| Nelson, MA | 1 |
| Bowden, GT | 1 |
| Rebel, H | 1 |
| van Steeg, H | 1 |
| Beems, RB | 1 |
| Schouten, R | 1 |
| de Gruijl, FR | 1 |
| Terleth, C | 1 |
| Reddig, PJ | 1 |
| Leitges, M | 1 |
| Croghan, MK | 1 |
| Aickin, MG | 1 |
| Meyskens, FL | 2 |
| Loescher, LJ | 1 |
| Gensler, HL | 1 |
| Reiners, JJ | 1 |
| Pavone, A | 1 |
| Rupp, T | 1 |
| Cantu, AR | 1 |
| Steven, FS | 1 |
| Williams, LA | 1 |
| Warne, P | 1 |
| Tucker, DF | 1 |
| Duvick, L | 1 |
| Ali, M | 1 |
| Talpaz, M | 1 |
| Plager, C | 1 |
| Quesada, J | 1 |
| Benjamin, R | 1 |
| Kantarjian, H | 1 |
| Gutterman, J | 1 |
| DiGiovanni, J | 1 |
| Kruszewski, FH | 1 |
| Chenicek, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm[NCT00601640] | Phase 2 | 184 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes[NCT05594563] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-03-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage. (NCT00601640)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.33 |
| Diclofenac Sodium | 0.26 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.64 |
Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant. (NCT00601640)
Timeframe: 3 months
| Intervention | nmol/g skin (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.03 |
| Diclofenac Sodium | 1.45 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.2 |
Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up. (NCT00601640)
Timeframe: 3 months
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning and Stinging None | Burning and stinging Mild | burning and stinging Moderate | Burning and Stinging Severe | Pruritis None | Pruritis Mild | Pruritis Moderate | Pruritis Severe | Rash, Redness. Erythema-None | Rash, Redness. Erythema-Mild | Rash, Redness. Erythema-Moderate | Rash, Redness. Erythema-Severe | |
| Diclofenac Sodium | 44 | 8 | 0 | 0 | 33 | 12 | 6 | 1 | 34 | 10 | 8 | 0 |
| Eflornithine Hydrochloride | 48 | 4 | 0 | 0 | 42 | 9 | 1 | 0 | 46 | 5 | 1 | 0 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 48 | 3 | 1 | 0 | 40 | 6 | 6 | 0 | 40 | 7 | 5 | 0 |
8 reviews available for eflornithine and Cancer of Skin
| Article | Year |
|---|---|
Polyamines and hair: a couple in search of perfection.
Topics: Animals; Eflornithine; Hair Follicle; Humans; Ornithine Decarboxylase; Ornithine Decarboxylase Inhib | 2010 |
Nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carc | 2011 |
Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential.
Topics: Adenosylmethionine Decarboxylase; Animals; Animals, Genetically Modified; Cell Line, Tumor; Cell Tra | 2007 |
Observations on the mechanism of skin tumor promotion by phorbol esters.
Topics: Adenosylmethionine Decarboxylase; Animals; Caenorhabditis elegans Proteins; Carrier Proteins; Cell D | 1983 |
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening.
Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas | 1993 |
The state-of-the-art in chemoprevention of skin cancer.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Eflornithine; Humans; Melano | 2000 |
Chemoprevention of human skin cancers.
Topics: Antineoplastic Agents; Eflornithine; Humans; Retinoids; Selenium; Skin Neoplasms | 1991 |
Inhibition of tumor promotion by DL-alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase.
Topics: Animals; Carcinogens; Colonic Neoplasms; Eflornithine; Female; Mammary Neoplasms, Experimental; Mice | 1990 |
8 trials available for eflornithine and Cancer of Skin
| Article | Year |
|---|---|
Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Topics: Eflornithine; Hearing; Hearing Loss; Humans; Ototoxicity; Skin Neoplasms | 2023 |
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Di | 2016 |
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Topics: Antineoplastic Agents; Audiometry; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Met | 2010 |
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Method; Eflornithine; Fem | 2012 |
Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoprevention; Efl | 2005 |
Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Biopsy; Breast Neoplasms; Colonic Neoplasms | 1998 |
Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Topics: Adult; Aged; Antineoplastic Agents; Chemoprevention; Eflornithine; Female; Humans; Immunosuppressive | 2001 |
Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Biopsy; Cell Division; Eflornithine; Enzy | 2002 |
32 other studies available for eflornithine and Cancer of Skin
| Article | Year |
|---|---|
Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport | 2009 |
Joint analysis of interval-censored failure time data and panel count data.
Topics: Antineoplastic Agents; Computer Simulation; Data Interpretation, Statistical; Eflornithine; Humans; | 2018 |
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice.
Topics: Administration, Topical; Animals; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diclof | 2014 |
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.
Topics: Animals; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2013 |
New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.
Topics: Anilides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Carotenoids; Cell Transformation, Neoplas | 2011 |
Difluoromethylornithine: the proof is in the polyamines.
Topics: Eflornithine; Female; Humans; Male; Skin Neoplasms | 2012 |
Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice.
Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Diclof | 2013 |
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Disease Progr | 2003 |
Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
Topics: Administration, Oral; Alopecia; Animals; Benz(a)Anthracenes; Carcinogens; Carcinoma, Squamous Cell; | 2003 |
Elevated levels of polyamines alter chromatin in murine skin and tumors without global changes in nucleosome acetylation.
Topics: Acetylation; Animals; Cell Transformation, Neoplastic; Chromatin; Chromobox Protein Homolog 5; Chrom | 2003 |
Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis.
Topics: Animals; Eflornithine; Enzyme Induction; Female; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred ICR; | 2005 |
Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine.
Topics: Adenosylmethionine Decarboxylase; Administration, Oral; Administration, Topical; Animals; Cell Divis | 1983 |
Polyamine biosynthesis and skin tumor promotion: inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin tumor formation by the irreversible inhibitor of ornithine decarboxylase alpha-difluoromethylornithine.
Topics: Adenosylmethionine Decarboxylase; Animals; Carboxy-Lyases; Drug Antagonism; Eflornithine; Kinetics; | 1982 |
alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin.
Topics: Alkynes; Animals; Antineoplastic Agents, Phytogenic; Carboxy-Lyases; Carcinogens; Diterpenes; Eflorn | 1982 |
Effect of an inhibitor of tumor promotion, alpha-Difluoromethylornithine, on tumor induction by repeated beta irradiation in mice.
Topics: Animals; Anticarcinogenic Agents; Beta Particles; Dose-Response Relationship, Drug; Eflornithine; Fe | 1993 |
Polyamines regulate expression of the neoplastic phenotype in mouse skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Animals, Newborn; Apoptosis; Carcinoma, Papillary; Carcin | 1998 |
Chemopreventive effect of difluoromethylornithine (DFMO) on mouse skin squamous cell carcinomas induced by benzo(a)pyrene.
Topics: Animals; Benzo(a)pyrene; Carcinogens; Carcinoma, Squamous Cell; Eflornithine; Female; Hyperplasia; M | 1997 |
Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carcinogens; Eflornithine; Genes, | 1998 |
Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthocyanins; Carcinogens; Drug Screening Assays, Antitum | 1999 |
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Disease Progressio | 1999 |
Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Crosses, Genetic; Eflornithine; | 2000 |
Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Cell Division; Eflornithine; Enzyme Inducti | 2001 |
Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice.
Topics: Animals; Anticarcinogenic Agents; DNA Repair; DNA-Binding Proteins; Eflornithine; Enzyme Inhibitors; | 2002 |
Protein kinase Cdelta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Cell Cycle Proteins; Cell Division; Eflornit | 2002 |
Dose-related alpha-difluoromethylornithine ototoxicity.
Topics: Adolescent; Adult; Age Factors; Aged; Audiometry; Dose-Response Relationship, Drug; Drug Evaluation; | 1991 |
Prevention by alpha-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation.
Topics: Animals; Eflornithine; Female; Immunosuppression Therapy; Mice; Mice, Inbred BALB C; Phenotype; Skin | 1991 |
Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cocarcinogenesis; Eflornithine; Female; Interferon-gamma; | 1990 |
Fluorescent location of ornithine decarboxylase employing derivatives of the specific inhibitor alpha-difluoromethyl ornithine.
Topics: Animals; Binding, Competitive; Carcinoma, Squamous Cell; Eflornithine; Fluorescent Dyes; Humans; Mic | 1989 |
Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and alpha-difluoromethylornithine.
Topics: Animals; Diet; Eflornithine; Female; Isotretinoin; Mice; Mice, Inbred Strains; Ornithine; Ornithine | 1986 |
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Gastrointestinal Diseases | 1986 |
Modulation of chrysarobin skin tumor promotion.
Topics: Animals; Anthracenes; Carcinogens; Cocarcinogenesis; Eflornithine; Female; Fluocinolone Acetonide; M | 1988 |